To include your compound in the COVID-19 Resource Center, submit it here.

Myrexis cancer, infectious news

Myrexis disclosed in its 4Q11 earnings ended June 30 that it is discontinuing development of Azixa verubulin, a small molecule microtubule destabilizing apoptosis-inducer in Phase IIb testing for glioblastoma multiforme (GBM). According to

Read the full 331 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE